Has the new USP assay for heparin affected dosage for patients undergoing cardiopulmonary bypass?

Journal of Extra-Corporeal Technology

Volumn 45, Issue 2, 2013, Pages 112-115

  Anderson, Daniel A ^a,b   Holt, David W ^b  

^a New Hampshire Dartmouth Psychiatric Research Center   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Blood; Cardiovascular; CPB; Heparin; N heparin; Pharmacology; USP monograph

Indexed keywords

HEPARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CLINICAL PROTOCOL; CORONARY ARTERY BYPASS GRAFT; ELECTIVE SURGERY; HUMAN; IN VIVO STUDY; LABORATORY TEST; LOADING DRUG DOSE; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY;

EID: 84881526689     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Blossom DB. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med. 2008;359:2674.
2. Change in heparin USP monograph [Internet]. FDA; 2009 [updated 10/1/2009]. Available at: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM112597. Accessed December 1, 2012.
3. Kishimoto TK. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008;358:2457.
4. FDA public health alert: Change in heparin USP monograph [Internet]. FDA; 2009 [updated 10/1/2009]. Available at: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm184502.htm. Accessed December 1, 2012.
5. Smythe MA, Nutescu EA, Wittkowsky AK. Changes in the USP heparin monograph and implications for clinicians. Pharmacotherapy. 2010;30:428-31.
6. Drug safety podcasts > podcast for healthcare professionals: Follow up to the public health alert about changes to the heparin sodium USP monograph [Internet]. FDA; 2010 [updated 04/15/2010]. Available at: www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm208545.htm. Accessed December 1, 2012.
7. Honchel R, Carraway J, Gopee N, et al. A dose-response study in animals to evaluate the anticoagulant effect of the stage 2 unfractionated heparin USP monograph change. Regul Toxicol Pharmacol. 2011;60:318-22.
8. Bull BS. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg. 1975;69:685.
9. ACCP newsletter-FDA announces new standards for heparin-October 12, 2009 [Internet]. 2009. Available at: www.chestnet.org/accp/article/fda-announces-new-standards-heparin. Accessed February 23, 2011.